Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective, Randomized, Double-Blind, Multi-Center Trial to Assess the Safety and Efficacy of ASCEND Investigational Drug-Coated Balloon for Sinus Dilation

Next Previous
Trial Profile

A Prospective, Randomized, Double-Blind, Multi-Center Trial to Assess the Safety and Efficacy of ASCEND Investigational Drug-Coated Balloon for Sinus Dilation

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 15 Oct 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mometasone (Primary)
  • Indications Sinusitis
  • Focus Therapeutic Use
  • Sponsors Intersect ENT

Most Recent Events

  • 07 Oct 2019 Status changed to completed, according to an Intersect ENT media release.
  • 07 Oct 2019 Primary endpoint (Intra-patient comparison of frontal sinus patency grade at day 30, as judged by an independent reviewer: superiority of investigational ASCEND product against an uncoated balloon control) has not been met, according to an Intersect ENT media release.
  • 07 Oct 2019 According to an Intersect ENT media release, as the first trial of its kind for this product platform, the company recognized that the outcomes of the ASCEND trial could require further clinical study to support PMA approval with the U.S. Food and Drug Administration.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top